ArticleCellular and molecular neurobiology2025
Fibrinogen and Complement Factor H Induce Parkinsonian and Cognitive Impairment-Like Features in Mice.
Article in Cellular and molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Irisin-integrin αV/β5 coupling of α-synuclein phagocytosis and clearance.Journal of neuroinflammation · 2026Article
- Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson's Disease.Annals of neurosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cognitive impairment is one of the non-motor symptoms of Parkinson's disease (PD), which may precede motor impairment. Biomarker(s) can help detect the cognitive dysfunction, much earlier in the disease and may differentiate PD patients with and without cognitive impairments. Animal model-based biomarker validation studies can provide better insights into pathogenesis and open up avenues for addressing therapeutics; however, such studies using non-genetic modalities, are few. Our earlier non-targeted label-free proteomics-assisted biomarker study on CSF of PD patients with cognitive impairment (PDCI), revealed the presence of elevated levels of fibrinogen and complement factor H (CFAH) in PDCI-CSF. We now intend to determine if these proteins harbor a pathogenic potential, when present above physiological levels. Native fibrinogen and recombinant CFAH were intraperitoneally injected in adult C57BL/6J mice and 48 h later the motor and cognitive behavior alongside neuroanatomical correlates were studied. The motor and cognitive deficits were complemented by degenerative changes in the SNpc, striatum, CA1 and subiculum in the injected mice. The altered gut microarchitecture suggests the possibility of other non-motor symptoms. Here, we show that fibrinogen and CFAH can potentially induce motor, and non-motor deficits in mice, akin to the PDCI-associated neuropathological deficits, and thus are potential biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.